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Abstract: Objectives. The present study summarizes available evidence describing efficacy  
of pharmacological methods used in smoking cessation and presents the results of new meta-analyses 
examining their 12-month efficacy. This work represents part of a larger program examining the efficacy and 
cost-effectiveness of different methods used in smoking cessation. Patients and methods. The first part  
of the study included systematic review of literature to identify methods used in smoking cessation with efficacy 
confirmed on the basis of existing reliable systematic reviews or meta-analyses. In the second stage  
of the process, for the interventions judged both available in Poland (on the basis of literature search and 
interviews with healthcare providers) and efficacious, we have performed new meta-analyses designed  
to establish their 12-month efficacy (continuous or prolonged abstinence). Results. We found that the most 
comprehensive and up-to-date data were available in Cochrane reviews. Meta-analyses of randomised 
controlled trials performed in the second part of the work showed that adding pharmacological methods  
of smoking cessation available in Poland, such as nicotine replacement therapy (NRT) and bupropion,  
to nonpharmacological methods increased the probability of smoking cessation and smoking abstinence for ≥12 
months by over 1.5 to about 3 times and the number needed to treat to have one patient stop smoking ranged 
from 8 to 21. Conclusions. We confirmed that pharmacological methods of smoking cessation available in 
Poland, such as NRT and bupropion, added to nonpharmacological methods increase the probability of smoking 
abstinence and we quantified 12-month effects of these interventions.
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INTRODUCTION
Tobacco dependence is a disease specified in the 10th Re-
vision of International Classification of Diseases [1]. A half of 
long-term smokers are estimated to die due to tobacco depen-
dence with 50% of these cases in a productive age. Tobacco 
use is a predominant risk factor for lung cancer, as well as 
cardiovascular and respiratory system diseases [2-4]. Available 
data in 1990 for the Polish population of 35–69 years showed 
that 91% of lung cancer cases in men and 65% in women, 
58% of all cancer cases in men and 8% in women and 42% of 
cardiovascular diseases in men and 11% in women as well as 
71% of respiratory diseases in men and 36% in women, were 
directly caused by smoking [5].  
At present 34% of men and 22% of women in Poland 
are smokers [5]. Estimates show that annual expenditures on 
treatment of smoking related diseases in Poland amount to 
18 billion PLN [6], and if a prevalence of smoking does not 
change, the direct cost of treatment within 20 years will reach 
198 billion PLN [7]. 
Smoking cessation brings substantial health benefits. 
A systematic review of 20 prospective cohort studies showed 
that smoking cessation, even among subjects with already di-
agnosed ischemic heart disease, is associated with a reduction 
in risk of death from any cause (relative risk [RR] 0.64, 95% CI 
0.58–0.71), as well as in the risk of recurrent myocardial infarc-
tion (RR 0.68, 95% CI 0.57–0.82) [8]. Reduction in the risk of 
death from any cause associated with smoking cessation in pa-
tients with ischemic heart disease is more pronounced than that 
associated with any other secondary prophylaxis intervention: 
β-blockers (OR 0.77, 95% CI 0.57–0.85) [9] or angiotensin con-
verting enzyme inhibitors (OR 0.8, 95% CI 0.74–0.87) [10]. 
Reduction in smoking prevalence in Poland by introduc-
ing the interventions of confirmed efficacy into tobacco de-
pendence treatment may result in the reduction in morbidity 
and mortality due to smoking related diseases, thus in cost 
reduction. 
Identification of methods used for tobacco dependence 
treatment based on systematic review and their efficacy analy-
Correspondence to:
Małgorzata M. Bała, MD, PhD, II Katedra Chorób Wewnętrznych Collegium Medi-
cum Uniwersytetu Jagiellońskiego, ul. Skawińska 8, 31-066 Kraków, Poland, phone: 
+48-12-293-42-36, fax: +48-12-293-40-30, e-mail: gosiabala@mp.pl
Received: December 12, 2007. Accepted in final form: January 1, 2008.
Conflict of interest: none declared.
Pol Arch Med Wewn. 2008; 118 (1-2): 20-28
Translated by Kajetana Foryciarz, MD
Copyright by Medycyna Praktyczna, Kraków 2008
Efficacy	of	pharmacological	methods	used	for	treating	tobacco	dependence:	meta-analysis		 21
ORIGINAL ARTICLES
sis based on reliable scientific research will make it possible to 
determine which of them could be of benefit and should be 
applied on a wider scale. 
The objective of the study was to assess the efficacy and 
cost-effectiveness of methods used in the tobacco dependence 
treatment. The current report deals only with analysis of ef-
ficacy of pharmacological methods used in smoking cessation.
PATIENTS	AND	METHODS
The detailed description of methodology was presented in 
the previous paper [11]. In brief, the study presented included 
2 phases:
1. Systematic review of data to identify pharmacological 
methods of smoking cessation treatment and preliminary ef-
ficacy evaluation on the basis of existing reliable systematic 
reviews and meta-analyses of randomized trials (abstinence af-
ter at least 6 months from the start of treatment). Twenty-five 
electronic databases were searched i.a. CINAHL, EMBASE, 
MEDLINE, via PubMed, ProQuest, PsycINFO for the period 
until March 2004 and Cochrane Library in January 2005. 
Search was limited to studies performed in adults. The effi-
cacy of the identified methods in increasing of the probability 
of abstinence was assessed on the basis of existing reliable sys-
tematic reviews and meta-analyses. To be included in further 
analysis an intervention was required to have its efficacy i.e. 
a significant difference in the percentage of individuals remain-
ing in continuous abstinence after at least 6 months from the 
beginning of therapy, shown in a reliable systematic review or 
meta-analysis. The results of all the reviews were summarized, 
and the most up-to-date reliable systematic reviews were se-
lected for further analysis.
2. Availability of individual tobacco dependence treatment 
methods in Poland was defined based on the available data 
and interviews with health service providers. Original stud-
ies, where the treatment efficacy was expressed as 12-month, 
continuous or prolonged tobacco abstinence [see below] (irre-
spective of the year of the study publication and the number of 
persons subjected to intervention) were extracted from reliable 
systematic reviews and meta-analyses, which were used for 
initial efficacy assessment; the studies, where abstinence was 
assessed only during the week preceding the medical control, 
were excluded. 
In the next stage, meta-analysis of data from those stu- 
dies was performed and their impact on achieving at least 
a 12-month continuous abstinence (refraining from smoking 
from the moment of smoking cessation for the period of 12 
months; occasional slips/lapses are possible) or prolonged absti-
nence (refraining from smoking from the moment of smoking 
cessation for 12 months; during the first two weeks from the 
target date of smoking cessation, isolated lapses are possible) 
was defined. Application of data concerning the 12-month ab-
stinence was associated with the fact that the available epide-
miological data (risk of death and risk of disease) used in cost-
effectiveness analysis and an economic model cover 12-month 
periods. Moreover, tobacco abstinence lasting at least one year 
provides a good chance of total success. The data for meta-
analysis were extracted from primary studies included in the 
analysis. 
RESULTS
In Table 1 there are listed systematic reviews and meta- 
-analyses assessing the efficacy of pharmacological tobacco de-
pendence treatment methods that were found during the first 
stage of the study.
The most complete and up-to-date data were included in 
the reviews made in accordance with Cochrane Collaboration 
methodology.
During the study, among the pharmacological treatment 
methods, whose efficacy was unambiguously confirmed, the 
following were available in Poland: bupropion and nicotine 
Table 1. Tobacco dependence treatment methods which efficacy was assessed in systematic reviews or meta-analyses found
Intervention Number of systematic reviews/meta-analyses 
(years of publication)
Cochrane review, last search
Nicotine replacement therapy 9 (1987–2004) [12–20] March 2004 [18]a 
Bupropion 3 (2002–2004) [20–22] March 2004 [21]a
Clonidine 2 (1991–2004) [23,24] May 2004 [24]a
Nortriptiline 1 (2004) [21] the only review; March 2004 [21]
Other antidepressants 1 (2004) [21] the only review; March 2004 [21]
Anxiolytics 1 (2000) [25] the only review; August 2003 [25]
Opioid agonists 1 (2001) [26] the only review; March 2001 [26]
Lobeline 1 (1997) [27] the only review; May 1997 [27]
Mecamylamine 1 (1998) [28] the only review; February 2002 [28]
Citizine none none
a The most complete and up-to-date search
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assessed the effect of NRT added to simple advice, individual 
counseling or group therapy, on abstinence for 12 month (see 
appendix). All of those were randomized trials with control 
group not receiving NRT. In 29 studies efficacy of nicotine 
gums, in 19 – transdermal nicotine patches and in 2 – nicotine 
lozenge was assessed (see appendix).
The results of primary studies included in efficacy analysis 
were pooled by means of meta-analysis, and significant ben-
efits of NRT use were observed:
– in combination with simple advice – relative benefit incre-
ase (RBI) 64% (16 studies, Tab. 2, Fig. 1),
– in combination with individual counseling – RBI 52% 
(19 studies, Tab. 2, Fig. 2),
– in combination with group therapy – RBI 63% (15 studies, 
Tab. 2, Fig. 3).
2. Bupropion
Available reviews 
Efficacy of bupropion in comparison with the control group 
receiving placebo and individual counseling or group therapy, 
was confirmed in 3 reviews and meta-analyses published be-
tween 2002–2004 (OR 2.75, 95% CI 1.98–3.81 [20]; 23–35% 
vs. 12–16%, p <0.05) [22]; OR 2.06, 95% CI 1.77–2.4 [21]).
The commonly observed adverse events of bupropion 
treatment were insomnia (30–40% vs. 20%), mouth dryness 
10–13% vs. 4.5%) and nausea [21,30]. Symptoms that caused 
withdrawal from the study were observed in 5–12% of pa-
tients receiving bupropion as compared with 4–8% of patients 
receiving placebo [20]. Treatment with bupropion may be as-
sociated with seizures (1/1,000 patients receiving bupropion in 
an open, non-controlled trial; similar occurrence in national 
registry of adverse events and clinical trials), allergic reactions 
– itching, allergic dermatitis, angioedema, dysponea (1–3/1000 
in clinical trials and national registry of adverse events) [20,21]. 
In observational trials after the drug was launched, the symp-
toms of joint pain, muscle pain, fever and rash were reported, 
serum sickness-like symptoms (less than 1/1000) and suicidal 
thoughts (1/667 in clinical trials, 1/10,000 in national registry 
of adverse events) [20,21]. In the safety assessment provided 
by the European Agency for the Evaluation of Medicines for 
Human Use [21,31], occurrence of suicidal thoughts during 
bupropion therapy is mentioned to be low as compared to the 
general population, but no data was shown. The Agency rec-
ommended placing a warning message about possible hyper 
reactivity and depression in the drug information leaflet. Ac-
cording to the Agency, the benefits outweigh the harm ob-
served during therapy with bupropion. 
Efficacy analysis in achieving the 12-month 
abstinence
In the Cochrane review [21] the most up-to date efficacy 
data were included; the last search was performed in 2004. 
replacement therapy (nicotine gum, transdermal patches, loz-
enge – approved and available; inhaler and nasal spray – ap-
proved but unavailable).
1. Nicotine replacement therapy (NRT)
Available reviews 
Nine meta-analyses and systematic reviews were found pub-
lished in 13 papers from 1987 to 2004. In 2 of those efficacy 
of nicotine gum alone was assessed [12,16] and its efficacy in 
tobacco abstinence comparing to no nicotine gum was shown, 
especially if provided in specialized centers (27% vs. 18% [16]). 
In three papers efficacy of nicotine transdermal patch alone 
was assessed [13,14,17] and its efficacy comparing to placebo 
was shown (OR 3.0 [13]; OR 2.3, 95% CI 1.6–3.4 [14]; OR 
2.26 [17]).
Similar results were obtained in 2 reviews assessing nico-
tine gum and transdermal patches efficacy in patients treated 
in therapeutic program or according to medical advice (nico-
tine gum – risk difference [RD] 6%, 95% CI 4–8%; transder-
mal patches – RD 9%, 95% CI 6–13% [19]), as well as with-
out any medical advice or as over-the-counter (OTC) drugs 
(OR 2.5, 95% CI 1.8–3.6) [15].
In the HTA report assessing NRT and bupropion efficacy 
[20] and in Cochrane review, first published in 1994, continu-
osly updated [18], all the NRT methods were assessed. Probabil-
ity of continuous abstinence for 6 months comparing with non-
NRT treatment was shown to be significantly higher (OR 1.72, 
95% CI 1.61–1.84 [20]; OR 1.75, 95% CI 1.64–1.87 [18]).
Commonly observed adverse events for nicotine gum treat-
ment were: hiccup, gastro-intestinal symptoms, jaw pain, tooth 
and periodontal diseases; for transdermal patches – mild der-
matitis (25% vs. 13%); and sublingual tablets – hiccup, feeling 
of burning or smarting sensation in the mouth, sore throat, 
dryness of lips and mouth ulcers [18,20]. Serious adverse events 
and adverse events resulting in study withdrawal were equally 
frequent in NRT group and control (4% vs. 2.5%) [20]. In the 
review regarding adverse events of transdermal patches, that 
included 35 studies, a low occurrence of cardiovascular symp-
toms was shown, not increased compared with the control group 
(myocardial infarction 1% vs. 1%; stroke 0.3% vs. 1%; angina 
0.4% vs. 0.4%, arrhythmia 3% vs. 2%, hypertension 2% 
vs. 1%) [18,20,29]. The observation provided by FDA showed 
that adverse effect occurrence is 12.3/million of patients for 
nicotine gum and 11.8/million for transdermal patches [20]. 
Efficacy analysis in achieving the 12-month 
abstinence
In the Cochrane review the most up-to date efficacy data 
were included; the last search was performed in 2004. The 
references of papers included were compared with references of 
papers included to the remaining reviews/meta-analyses. 
From among 103 papers incorporated in Cochrane system-
atic review [18], 50 were included in efficacy analysis, which 
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The references of papers included were compared with refer-
ences of papers included to remaining reviews/meta-analyses. 
From among 24 papers incorporated in the systematic 
review [21], 11 were included in efficacy analysis which as-
sessed the effect of bupropion added to individual counseling 
or group therapy, on abstinence for 12 months (see appendix). 
All of those were randomized trials with control groups receiv-
ing individual counseling or group therapy and placebo. 
The results of primary studies included in efficacy analysis 
were pooled by means of meta-analysis, and significant bene-
fits were observed:
– of bupropion added to individual counseling compared 
with counseling and placebo – RBI 74% (8 studies, Tab. 2, 
Fig. 4)
– of bupropion added to group therapy compared with gro-
up therapy and placebo – RBI 185% (3 studies, Tab. 2, 
Fig. 5). However, the patient groups in those studies were 
small, in one of those in the control group no one stopped 
smoking, therefore confidence intervals for that treatment 
effect are wide.
3. Bupropion together with NRT
Bupropion used along with NRT comparing with placebo was 
assessed in one trial (together with individual counseling in both 
groups) [21,32]. A significant benefit was observed (Tab. 2). How-
ever, this result was obtained from 1 study with low precision.
4. Other pharmacological methods used for 
treating tobacco dependence
Moreover, unambiguous data confirming efficacy in 
achieving abstinence with clonidine use (OR 1.89, 95% CI 
1.30–2.74) [24], which is not approved for treating tobacco 
dependence in Poland and nortriptyline (OR 2.79, 95% CI 
1.70–4.59) [21], which is not available in Poland were found. 
Therefore they were not taken into consideration in efficacy 
analysis of achieving the 12-month abstinence. 
In the systematic reviews or meta-analyses we found the 
efficacy of the following methods was not confirmed:
– antidepressants other than bupropion and nortriptyline [21]
– anxiolytics [25]
– opioid antagonists [26]
– lobeline[27]
– mecamylamine [28].
No randomized studies for cytyzine were found [33,34].
DISCUSSION
In the studies included in the meta-analysis 1 year, prob-
ability of abstinence ranges between 0% and 38.5% in con-
trol groups, 8.8% and 43% in bupropion group and 3.1% and 
52.4% in the NRT group. Estimated abstinence rate was in 
controls 5.6–20.4% and in treated groups – 12.9% for NRT 
to 33.3% for bupropion.
In the systematic reviews analysis and in a meta-analyses 
of randomized trials concerning pharmacological methods of 
tobacco dependence treatment, the efficacy of methods avail-
able in Poland i.e. bupropion and nicotine replacement therapy 
in increasing a 12-month probability of tobacco abstinence 
was confirmed. Adding bupropion was associated with a 2-fold 
increase of probability of smoking cessation and abstinence for 
12 months comparing with individual counseling alone and 
about 3 fold increase compared to the group therapy alone 
with number need to treat (NNT) 14 and 9, respectively. 
Table 2. Efficacy of individual pharmacological tobacco dependence treatment methods in achieving a 12-month abstinence
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NNT – number needed-to-treat, NRT – nicotine replacement therapy
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Adding of NRT to simple advice (short intervention last-
ing ≤10 min with at most 1 control visit), individual counsel-
ing or group therapy, increased the probability of smoking ces-
sation about 1.5 times comparing with the respective control 
group with NNT 8–21. Moreover, adding NRT together with 
bupropion to individual counseling increased that probabil-
ity about 4 times with NNT 6. However, the value of these 
data should not be overestimated because it comes from one 
randomized study with a wide confidence interval for relative 
benefit (95% CI 2.08–7.8).
When the analysis was performed, the only available 
methods of NRT in Poland were nicotine gums, transder-
mal patches and lozenges. However, lately, also inhalers and 
sublingual tablets become available. According to Cochrane 
review meta-analyses, those methods increase the probability 
of  smoking cessation in at least 6 months observation simi-
lar to other methods – about 2 times (OR for inhalers: 2.14, 
95% CI 1.44–3.18; OR for lozenges and sublingual together: 
2.05, 95% CI 1.62–2.59) [18]. 
The results presented are consistent with results of other 
studies and with recommendations regarding treatment of to-
bacco dependence which mention bupropion and nicotine re-
placement therapy as a first-line treatment [35-38]. 
During the current search none of randomized trials with cit-
izine, the medication available in Poland for 40 years, was found. 
However, authors of systematic review published in 2007 [39], 
which assessed the efficacy of partial nicotine receptor agonists, 
found a randomized study of poor quality, performed in the ear-
ly 1970 in a single nicotine dependence treatment center in East 
Germany [40]. The abstinence according to the patient report was 
0.2 0.5 1 2 5 10
RB = 1.64 (95% CI 1.45–1.87)
Relative benefit
p <0.0001, χ2 test = 58.2, df = 1; 
Q test = 23.3, df = 15, p = 0.08
RB for study with 95% CI CI out of scale
















Fig. 1. Efficacy of nicotine replacement therapy added to simple 
advice in achieving 12-month abstinence – relative benefit (RB) vs. 
simple advice alone. References – see appendix
RB = 1.52 (95% CI 1.35–1.70)
p <0.0001, χ2 test = 52.6, df = 1; 
Q test = 31, df = 18, p = 0.03
RB for study with 95% CI CI out of scale



















Gums – Campbell '91
 Sublingued tablets –  
     Shiffman '02a
Fig. 2. Efficacy of nicotine replacement therapy added to individu-
al counseling in achieving 12-month abstinence – relative benefit 
(RB) vs. individual counseling alone. References – see appendix
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co related diseases [8,42-44]. In analyses performed in other 
countries different methods of smoking cessation support were 
found cost-effective. The cost effectiveness of smoking cessation 
supporting interventions is much more pronounced than in the 
majority of medical interventions at all levels of medical care [45]. 
However despite that, those interventions are often not refund-
ed by health care providers. According to some authors, NRT 
and bupropion are one of the most cost effective interventions 
in health care system [46]. In the study assessing 500 life-
saving interventions the median of costs was 42,000 USD per 
life year gained (1993) with the majority of widely used inter-
ventions costing 100,000 USD per life year gained. Compared 
with that: in European studies incremental cost effectiveness 
(the additional cost for the additional health effect) of differ-
ent NRT added to medical counseling is 3113–6879 EUR per 
life year gained in male and 3779–8799 EUR per life year 
gained in female [47]; moreover, if bupropion was added to 
individual counseling the incremental cost per life year gained 
was estimanted in one study to be 639–1278 GBP [20], an id 
the another 1,768–2,851 EUR in male and 2146–3646 EUR 
in female [47].
The reimbursement of tobacco dependence treatment may 
be an interventia increasing probability of smoking cessation 
assessed after 4 weeks, 6 months and 2 years of treatment. The 
probability of smoking cessation in the citizine group compared 
with placebo increased more than 1.5 times (OR 1.77, 95% CI 
1.3–2.4). At present there is a randomized clinical trial 
ongoing in Poland with the purpose of citizine efficacy as-
sessment [41]. On the basis of citizine the varenicline, partial 
nicotine receptor agonist was developed, which was launched 
in Poland in 2007. Its efficacy in increacing the probability of 
12 month abstinence was confirmed in 5 randomized studies 
(OR 3.22, 95% CI 2.43–4.27). In 3 of these studies more pa-
tients stopped smoking and remained abstinent for 12-months 
in the varenicline group than in the bupropion group (OR 1.66, 
95% CI 1.28–2.16) [39]. In the recent recommendations of the 
European Respiratory Society regarding tobacco dependence 
treatment in patients with respiratory diseases, varenicline was 
mentioned as a second-line treatment [37].
Clinical studies confirmed that smoking cessation is associ-
ated with mortality and morbidity risk reduction due to tobac-
RB = 1.63 (95% CI 1.41–1,88)
RB for study with 95% CI CI out of scale
















Gums – Blondal '89
p <0.0001, χ2 test = 44.9, df = 1; 
Q test = 7.3, df = 14, p = 0.9
Fig. 3. Efficacy of nicotine replacement therapy added to group 
therapy in achieving 12-month abstinence – relative benefit (RB) 
vs. group therapy alone. References – see: appendix
RB = 1.74 (95% CI 1.45–2.09)
RB for study with 95% CI CI out of scale
0.50.2 1 2 5
Relative benefit
p <0.0001, χ2 test = 35, df = 1; 










Fig. 4. Efficacy of bupropion therapy added to individual counse-
ling in achieving 12-month abstinence – relative benefit (RB) vs. 
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by itself. Cochrane systemic review [48] showed that, compar-
ing to partial or no reimbursement, the total treatment cost 
reimbursement may increase a probability of the abstinence for 
at least 6 months (OR 1.48, 95% CI 1.17–1.88), the probabili-
ty of smoking cessation attempt (OR 1.32, 95% CI 1.18–1.49), 
use of pharmacologic substances supporting smoking cessa-
tion (for NRT: OR 2.92, 95% CI 1.49–5.71; for bupropion: 
OR 2.47, 95% CI 0.85–7.13) and non-pharmacological meth-
ods (OR 3.67, 95% CI 3.06–4.39). However, the differences 
between groups were not significant and poor study method-
ology require caution in the interpretation of the review re-
sults. The cost-effectiveness analyses showed that incremental 
cost of abstinence achieved by one smoker with total cost re-
imbursement comparing with no reimbursement is 1247 USD. 
Those results were confirmed in other studies [49,50]. 
In Great Britain the reimbursement of bupropion and NRT 
costs for smokers willing to cease, together with counseling 
was introduced in two stages; initially for two weeks (NRT) 
and 3–4 weeks (bupropion) and, if during the follow-up visit 
the patient maintains abstinence, the cost reimbursement is 
prolonged for the following treatment period. If the smoking 
cessation attempt with those pharmacological substances fails, 
next prescription can not be made during the next 6 months. 
The cost reimbursement of pharmacological substances sup-
porting smoking cessation was introduced in New Zealand. 
The cost reimbursement of pharmacological methods used for 
treating tobacco dependence should also be considered by Po- 
lish health care providers. 
1 2 5
RB = 2.85 (95% CI 1.53–5.30)
RB for study with 95% CI
p = 0.0009, χ2 test = 10.9, df = 1; 





Fig. 5. Efficacy of bupropion therapy added to group therapy in 
achieving 12-month abstinence – relative benefit (RB) vs. group 
therapy alone. References – see appendix
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